Global Blood Therapeutics (GBT) Falls on Negative Analyst Chatter
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Global Blood Therapeutics (NASDAQ: GBT) is down 7.6% Wednesday amid talk of a negative call from Favus on the stock.
Shares of GBT are higher over the last several days following a bullish call from Wells Fargo's Jim Birchenough.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jim Chanos Negative Again on Valeant Pharma (VRX) in CNBC Interview
- Option volume flows
- Stocks with Implied Volatility Movement